Jasper Therapeutics (JSPR) EBITDA (2019 - 2026)
Jasper Therapeutics (JSPR) EBITDA from Aug 30, 2019 to Mar 31, 2026. The TTM Jasper Therapeutics (JSPR) EBITDA is -$72M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Jasper Therapeutics (JSPR) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -11.48% |
| 3 Years TTM | +12.06% |
| 5 Years TTM | +12.92% |
| All Time TTM | +72.61% |
Annual EBITDA change of Jasper Therapeutics (JSPR)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$11M | -86.80% |
| 2025 | -$83M | +10.63% |
| 2024 | -$75M | +10.51% |
| 2023 | -$68M | +34.91% |
| 2022 | -$50M | +37.74% |
| 2021 | -$36M | +15.27% |
| 2020 | -$32M | N/A |
| 2019 | $0 | N/A |
Comparison Jasper Therapeutics (JSPR) five years EBITDA CAGR with competitors
Jasper Therapeutics (JSPR) five years EBITDA CAGR is 12.92%.